NEW YORK (GenomeWeb News) – Celltrion will evaluate Crucell’s cell lines for use in its drug development services programs under a new licensing agreement, Crucell said today.
The non-exclusive agreement allows Celltrion to evaluate Crucell’s STAR technology, which is used in producing recombinant human antibodies and proteins, for its drug programs, Crucell said.
Crucell’s STAR technology contains genetic elements that enable stable gene expression that is used in making recombinant antibodies and proteins in mammalian cells. The Leiden, Netherlands-based firm said the technology can help increase the yields and lower the costs of antibody and protein production.
Celltrion offers services including cell line development and banking, process development, as well as technical, quality, and regulatory support services.
Financial terms of the agreement were not released.